Susceptibility of gram-positive and -negative bacteria to novel nitric oxide-releasing nanoparticle technology

Virulence

Volumn 2, Issue 3, 2011, Pages

  Friedman, Adam ^a   Blecher, Karin ^a   Sanchez, David ^b   Tuckman Vernon, Chaim ^b   Gialanella, Philip ^a   Friedman, Joel M ^b   Martinez, Luis R ^b,c   Nosanchuk, Joshua D ^a,b  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c LONG ISLAND UNIVERSITY   (United States)

Author keywords

Antibacterial; Gram negative; Gram positive; Nanotechnology; Nitric oxide

Indexed keywords

NANOPARTICLE; NITRIC OXIDE; ANTIINFECTIVE AGENT; DRUG CARRIER;

ABSCESS; ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORBIDITY; MORTALITY; NANOTECHNOLOGY; NONHUMAN; PSEUDOMONAS AERUGINOSA; SKIN INFECTION; SOFT TISSUE INFECTION; STREPTOCOCCUS PYOGENES; WOUND; DRUG EFFECT; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL VIABILITY; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; TIME;

ACINETOBACTER BAUMANNII; BACTERIA (MICROORGANISMS); ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MURINAE; NEGIBACTERIA; POSIBACTERIA; PSEUDOMONAS AERUGINOSA; STREPTOCOCCUS PYOGENES;

ANTI-BACTERIAL AGENTS; DRUG CARRIERS; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; NANOPARTICLES; NITRIC OXIDE; TIME FACTORS;

EID: 79959231672     PISSN: 21505594     EISSN: 21505608     Source Type: Journal    
DOI: 10.4161/viru.2.3.16161     Document Type: Article

References (29)

1. Hoiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O. Antibiotic resistance of bacterial biofilms. Intl J Antimicrob Agent 2010; 35:322-332.
2. Shenoy MS, Bhat GK, Kishore A, Hassan MK. Significance of MRSA strains in community associated skin and soft tissue infections. Indian J Med Microbiol 2010; 28:152-154.
3. Maragakis LL, Perl TM. How can we stem the rising tide of multidrug-resistant gram-negative bacilli? Infect Control Hosp Epidemiol 2010; 31:338-340.
4. Maragakis LL, Perencevich EN, Cosgrove SE. Clinical and economic burden of antimicrobial resistance. Expert Rev Anti Infect Ther 2008; 6:751-763.
5. Boucher HW. Challenges in anti-infective development in the era of bad bugs, no drugs: a regulatory perspective using the example of bloodstream infection as an indication. Clin Infect Dis 2010; 50:4-9.
6. Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Scheld WM, et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:155-164.
7. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1-12.
8. Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay and health care costs. Clin Infect Dis 2006; 42:82-89.
9. Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis 2003; 36:1433-1437.
10. Friedman AJ, Han G, Navati MS, Chacko M, Gunther L, Alfieri A, et al. Sustained release nitric oxide releasing nanoparticles: Characterization of a novel delivery platform based on nitrite containing hydrogel/glass composites. Nitric Oxide 2008; 19:12-20.
11. Hein S, Wang K, Stevens WF, Kjems J. Chitosan composites for biomedical applications: status, challenges and perspectives. Material Sci Technol 2008; 24:1053-1061.
12. Han G, Martinez LR, Mihu MR, Friedman AJ, Friedman JM, Nosanchuk JD. Nitric oxide releasing nanoparticles are therapeutic for Staphylococcus aureus abscesses in a murine model of infection. Plos One 2009; 4:7804.
13. Martinez LR, Han G, Chacko M, et al. Antimicrobial and healing efficacy of sustained release nitric oxide nanoparticles against Staphylococcus aureus skin infection. J Investig Dermatol 2009; 129:2463-2469.
14. Mihu MR, Sandkovsky U, Han G, Friedman JM, Nosanchuk JD, Martinez LR. Nitrix oxide releasing nanoparticles are therapeutic for Acinetobacter bau-manni wound infections. Virulence 2010; 1:62-67.
15. Martinez-Gutierrez F, Olive PL, Banuelos A, Orrantia E, Nino N, Sanchez EM, et al. Synthesis, characterization and evaluation of antimicrobial and cytotoxic effect of silver and titanium nanoparticles. Nanomedicine 2010; 6:681-688.
16. Ruparelia JP, Chatterjee AK, Duttagupta SP, Mukherji S. Strain specificity in antimicrobial activity of silver and copper nanoparticles. Acta Biomater 2008; 4:707-716.
17. Shrivastava S, Bera T, Roy A, Singh G, Ramachandararao P, Dash D. Characterization of enhanced antibacterial effects of novel silver nanoparticles. Nanotechnology 2007; 18:1-9.
18. Sanpui P, Murugadoss A, Prasad PV, Ghosh SS, Chattopadhyay A. The antibacterial properties of a novel chitosan-Ag-nanoparticle composite. Int J Food Microbiol 2008; 124:142-146.
19. Qi L, Xu Z, Jiang X, Hu C, Zou X. Preparation and antibacterial activity of chitosan nanoparticles. Carbohydrate Research 2005; 339:2693-2700.
20. Chadwick S, Kriegel C, Amiji M. Nanotechnology solutions for mucosal immunization. Adv Drug Deliv Rev 2010; 62:394-407.
21. Hamouda T, Baker JR Jr. Antimicrobial mechanism of action of surfactant lipid preparations in enteric Gram-negative bacilli. J Appl Microbiol 2000; 89:397-403.
22. Hamouda T, Hayes MM, Cao Z, Tonda R, Johnson C, et al. A novel surfactant nanoemulsion with broad-spectrum sporicidal activity against Bacillus species. J Infect Dis. Dec 1999; 180:1939-1949.
23. Pannu J, McCarthy A, Martin A, Hamouda T, Ciotti S, Fothergill A, Stucliffe J, et al. NB-002, a novel nanoemulsion with broad antifungal activity against dermatophytes, other filamentous fungi and Candida albicans. Antimicrob Agents Chemother 2009; 53:3273-3279.
24. Fang FC. Perspectives series: host/pathogen interac- r-tions. Mechanisms of nitric oxide-related antimicrobial activity. J Clin Invest 1997; 99:2818-2825.
25. Tavares AF, Nobre LS, Melo AM, Saraiva LM. A novel nitroreductase of Staphylococcus aureus with S-nitrosoglutathione reductase activity. J Bacteriol May 2009; 191:3403-3406.
26. Jarboe LR, Hyduke DR, Tran LM, Chou KJY, Liao JC. Determination of the Escherichia coli S-nitrosoglutathione response network using integrated biochemical and systems analysis. J Biol Chem 2008; 283:5148-5157.
27. Bang IS, Liu L, Vazquez-Torres A, Crouch ML, Stamler JS, Fang FC. Maintenance of nitric oxide and redox homeostasis by the salmonella flavohemoglobin hmp. J Biol Chem 2006; 281:28039-28047.
28. Frey AD, Farres J, Bollinger CJ, Kallio PT. Bacterial hemoglobins and flavohemoglobins for alleviation of nitrosative stress in Escherichia coli. Appl Environ Microbiol 2002; 68:4835-4840.
29. Han G, Friedman AJ, Friedman JM. Nitric oxide releasing nanoparticle synthesis and characterization. Methods Mol Biol 2011; 704:187-195.